Highwoods Needs 100K Sq Ft Monthly Leasing to Meet Year-End Goals

Answer outline

• What management is implicitly guiding for volumes over the next few quarters
  • The quarter that matters (and why it won’t automatically repeat)
  • The company’s stated forecasting framework (linear growth model)
• Role of Salesforce expansion and new sales reps: how soon does it show up, and what pace is realistic?
  • What was observed this quarter
  • How management frames the incremental timing
• Is sustained quarter-to-quarter growth beyond current levels expected?
  • Management’s explicit stance: outperforming records, but not necessarily “repeat immediately”
• Putting it together: the go-forward volume “trajectory” narrative
  • Expected near-term trajectory (next several quarters)
  • Expected medium-term trajectory (as Salesforce onboarding matures and adoption deepens)
• Final answer (directly addressing your question)

Answer outline

• Oshkosh’s 2026 demand outlook (what management is implying)
  • Company-level demand framing for 2026
• How backlog/order activity supports the demand outlook
  • Access segment (a key demand support for 2026)
  • Vocational segment (fire apparatus demand remains healthy, despite shipment timing)
  • Transport / NGDV and AeroTech (demand visibility with backlog conversion logic)
  • Jetway/backlog extension into 2027 as evidence of demand continuity
• Bottom line

Answer outline

• Key pipeline milestones achieved by Incyte in Q1 2026 (as disclosed on the Q1 2026 earnings call)
  • Immunology (povorcitinib) — major FDA regulatory acceptance + late-stage registration progress
  • Hematology (989, mutant CALR monoclonal antibody) — Phase III path advanced
  • Hematology (058, JAK2 V617F inhibitor) — Phase I dose-escalation advanced in Q1
  • Oncology (KRAS G12D inhibitor 734) — Phase III initiation in first-line pancreatic cancer
  • Immunology (povorcitinib, HS) — Phase III durability/response data presented
  • Oncology franchise updates that support pipeline-regulatory positioning (not “pipeline milestones” per se, but key Q1 events)
• Concise list of the most material Q1 2026 pipeline milestones

Answer outline

• Demand signals: data centers remain a key growth driver
• Backlog signals: RPO burn profile suggests a still-full pipeline, with timing extending modestly
• Booking cadence / book-to-bill context is discussed, but not quantified in the excerpt
• Operational constraint discussion: capacity ceiling is labor/leadership, not equipment procurement
• Bottom line (Q1 2026)

Answer outline

• Primarily constrained in March
• Expected to be constrained in June
• Direct implication for iPhone in June (context from Q&A)

Answer outline

• It signals material visibility into multi-year demand (not a one-quarter sales spike)
• It implies the market is willing to sign up to First Solar’s supply—subject to policy/pricing outcomes
• The backlog-to-deliveries timing suggests demand is already “under contract” but incremental growth may be uneven quarter-to-quarter
• Product and geography constraints can limit the ability to convert demand into incremental bookings quickly
• Bottom line

Answer outline

• Summary answer
• What Fiserv says AI spend is supposed to do for growth (not just cost)
  • AI is positioned as a revenue enabler via new “systems of collaboration” and new TAMs
  • Project Elevate (AI at the center) is expected to drive both revenue uplift and efficiency
  • AI revenue use cases are described as agentic capabilities in both Merchant and Banking
• How Fiserv intends to connect capex and investment to growth (and not let it derail margins)
  • Investments are “fully funded and fully resourced,” but Fiserv expects financial results to lag execution due to transition-year dynamics
  • Capex discipline and modernization are part of the funding story
• The resource side: efficiency actions to fund AI and capex without sacrificing growth
  • Specific efficiency actions already taken
  • Evidence of operational improvements that support revenue conversion
• Why 2026 is expected to be the “mid-single-digit visibility” year
  • Management frames 2026 as the year where execution improves before being fully visible
  • Yet management still anchors the growth target for 2026

Answer outline

• Demand trend: Microsoft Cloud strength remains broad-based and is translating into scaling AI capacity
• Backlog / deferred revenue signals: bookings + RPO point to a pipeline that supports future revenue (and hence future infrastructure needs)
• Infrastructure investment growth signals: capacity additions and GPU/data-center execution align with demand signals
• Supply-demand constraint and “backlog-to-growth” translation: constraints persist, with acceleration expected in the second half
• Consumption/usage model shift as a demand durability signal for AI compute infrastructure

Answer outline

• Sherwin-Williams’ pricing strategy for 2026 (as described in its Q1 2026 earnings materials)
  • 1) “Surgical” pricing: targeted rather than blanket increases
  • Using price + cost actions together (and planning for volatility)
  • Starting the year with an effective price increase and managing further steps based on the inflation baseline
  • Pricing execution supported by customer intimacy and agility
• How Sherwin-Williams approaches customer-specific pricing
  • 1) “Sit down with our customers” and build pricing into their procurement workflow
  • Methodical, end-market- and customer-tailored decisions
  • Limiting increases via cost reduction (reducing the need for uniform customer burden)
  • Being prepared to implement additional increases—while managing timing
• Bottom line

Answer outline

• Leasing demand is strengthening (velocity, volume, and tenant interest)
• Retention remains solid (a demand durability signal)
• Data-center–driven demand is creating incremental leasing demand
• Near-term “backlog proxy”: portion of 2026 leasing already addressed
• Supply constraints help support demand (and expected timing of vacancy)

Answer outline

• What exactly changed in guidance (announced on the Q1 2026 call)
  • Updated full-year 2026 revenue growth outlook (net of Medicare Cap impact)
  • Updated full-year 2026 EBITDA margin outlook (net of Medicare Cap impact)
• How Chemed described the Q1 drivers behind the VITAS guidance upgrade
• What VITAS reported in Q1 2026 (context for the guidance change)
• Important nuance: marketing costs rising constrained full-year margins for the consolidated company
• Bottom line (direct answer)